Multiple Sclerosis-Like Demyelinating Lesions During Adalimumab Treatment in a Case with Crohn’s Disease Crohn Hastalığı Olan Bir Olguda Adalimumab Tedavisi Sırasında Multipl Skleroz Benzeri Demiyelinizan Lezyonlar


Noropsikiyatri Arsivi, vol.59, no.4, pp.342-344, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.29399/npa.27973
  • Journal Name: Noropsikiyatri Arsivi
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, Psycinfo, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.342-344
  • Keywords: TNF-alfa blocker, adalimumab, multiple sclerosis, demyelination, Crohn?s disease, inflammatory bowel disease
  • Hacettepe University Affiliated: Yes


© 2021 by Turkish Association of Neuropsychiatry-.Tumor necrosis factor (TNF) antagonists have made significant progress in treating autoimmune diseases like inflammatory bowel disease. Adalimumab, a human anti-TNF monoclonal antibody, may be a treatment option for patients with moderate to severe Crohn’s disease for whom conventional treatments have not been effective. Central nervous system (CNS) and peripheral nervous system (PNS) demyelination may rarely develop during treatment. However, it is unclear whether CNS and PNS demyelination occurs as a coincidence or consequence. This report presents a 45-year-old male patient who developed multiple sclerosis-like demyelinating lesions at the seventh month of TNF alpha-blocker treatment. We discontinued anti-TNF therapy and initiated azathioprine. In the approximately eighteen-month follow-up, he did not show any neurological or radiological deterioration. When the autoimmune disease develops during anti-TNF blocker therapy, it would be a safe approach to choose a different group of biologic agents for disease control. The potential risk of developing neurological side effects requires closely follow-up of patients.